Which is preferred, itopride or levosulpiride, for treating functional dyspepsia or mild gastroparesis considering efficacy and safety?

Itopride vs Levosulpiride for Functional Dyspepsia

For functional dyspepsia, levosulpiride is preferred over itopride as a second-line treatment option based on superior efficacy demonstrated in network meta-analyses, though both agents are reasonable choices when first-line therapies fail.

Treatment Algorithm

First-Line Therapy (Use These First)

• Proton pump inhibitors (PPIs) at lowest effective dose 1
• H. pylori eradication if positive 1
• Consider histamine-2 receptor antagonists as alternative 1

Second-Line Therapy (When First-Line Fails)

Preferred approach:

1. Tricyclic antidepressants (TCAs) - Start amitriptyline 10 mg daily, titrate to 30-50 mg daily 1

   • Particularly effective for patients with overlapping abdominal pain or IBS
   • Strong recommendation with moderate quality evidence

2. Levosulpiride 25 mg three times daily 1

   • Network meta-analysis ranked levosulpiride as most effective prokinetic (77% probability of being rank 1) 2
   • Superior to 15 other drugs including itopride (OR 0.05-0.15) 2
   • Effective in 66% of patients by 15 days, with symptoms nearly resolved by 30 days 3

3. Itopride 100-200 mg three times daily 1

   • Response rates: 57-64% vs 41% placebo 4
   • Weak recommendation with low quality evidence 1

Direct Comparison: Levosulpiride vs Itopride

Levosulpiride advantages:

• Significantly superior efficacy in network meta-analyses 5, 2
• Ranked first overall (SUCRA 0.99) with RR 0.49 (95% CI 0.36-0.69) for symptom resolution 5
• Faster symptom improvement (>50% reduction by 15 days) 3
• Lower total adverse event profile compared to domperidone 6

Itopride advantages:

• Better long-term safety data - studied up to 12 months with 70-78% sustained response rates 7
• More robust trial quality with larger patient numbers (2620 patients in meta-analysis) 8
• Approved in Japan, Mexico, and Europe specifically for FD 7
• Dual mechanism: D2 antagonism + acetylcholinesterase inhibition 4, 8

Clinical Decision Points

Choose levosulpiride when:

• Maximum efficacy is priority
• Short-term treatment (4-8 weeks) planned
• Patient failed itopride previously
• Dysmotility-like symptoms predominate 3

Choose itopride when:

• Long-term treatment anticipated (>3 months)
• Levosulpiride unavailable (common in many countries)
• Patient has postprandial fullness and early satiety as primary symptoms 4, 8
• Concern about prolactin elevation (itopride: 3% incidence) 7

Safety Considerations

Both agents:

• Well-tolerated overall 1, 5
• Monitor for extrapyramidal symptoms (dopamine D2 antagonists)
• Assess efficacy at 4-8 weeks 1

Levosulpiride specific:

• Galactorrhea (26.7%), somnolence (17.8%), fatigue (11.1%) 3
• Dose: 25 mg three times daily (75 mg/day standard) 1, 3

Itopride specific:

• Minimal prolactin elevation (3%) 7
• No ECG changes identified 7
• Dose: Start 50 mg TID, optimal 100-200 mg TID 4
• Compliance >95% in long-term studies 7

Critical Caveats

Important limitations:

• Levosulpiride evidence based on smaller patient numbers (86 patients in highest-quality analysis) with low trial quality 5
• Neither agent addresses gastroparesis specifically - the 2025 AGA gastroparesis guidelines do not recommend either drug [9-9]
• For gastroparesis specifically: Use metoclopramide as first-line prokinetic (conditional recommendation, low certainty) 9
• Both agents unavailable in United States
• British Society of Gastroenterology gives weak recommendation for itopride (low evidence) but mentions levosulpiride as second-line option 1

The evidence strongly favors levosulpiride for pure efficacy in functional dyspepsia, but itopride offers better-documented long-term safety and may be more practical for extended treatment courses.